A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Döhner H, Späth D, Saadati M, Fiedler W, Götze K, Koller E, Westermann J, Vogel W, Heuser M, Lübbert M, Tischler HJ, Germing U, Teichmann LL, Fransecky L, Wölfler A, Nachbaur D, Hertenstein B, Schroers R, Martens U, von Harsdorf S, Radsak M, Aschauer G, Weißhaar S, Corbacioglu A, Schrade A, Gaidzik VI, Thol F, Paschka P, Bullinger L, Benner A, Döhner K, Ganser A

Open source

DOI: 10.1182/blood.2025030722
Published: 2026 Apr 9
Container: Blood
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/blood.2025030722,
  title = {A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.},
  author = {Döhner H and Späth D and Saadati M and Fiedler W and Götze K and Koller E and Westermann J and Vogel W and Heuser M and Lübbert M and Tischler HJ and Germing U and Teichmann LL and Fransecky L and Wölfler A and Nachbaur D and Hertenstein B and Schroers R and Martens U and von Harsdorf S and Radsak M and Aschauer G and Weißhaar S and Corbacioglu A and Schrade A and Gaidzik VI and Thol F and Paschka P and Bullinger L and Benner A and Döhner K and Ganser A},
  year = {2026},
  journal = {Blood},
  doi = {10.1182/blood.2025030722},
  url = {https://doi.org/10.1182/blood.2025030722}
}

RIS

TY  - JOUR
TI  - A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
AU  - Döhner H
AU  - Späth D
AU  - Saadati M
AU  - Fiedler W
AU  - Götze K
AU  - Koller E
AU  - Westermann J
AU  - Vogel W
AU  - Heuser M
AU  - Lübbert M
AU  - Tischler HJ
AU  - Germing U
AU  - Teichmann LL
AU  - Fransecky L
AU  - Wölfler A
AU  - Nachbaur D
AU  - Hertenstein B
AU  - Schroers R
AU  - Martens U
AU  - von Harsdorf S
AU  - Radsak M
AU  - Aschauer G
AU  - Weißhaar S
AU  - Corbacioglu A
AU  - Schrade A
AU  - Gaidzik VI
AU  - Thol F
AU  - Paschka P
AU  - Bullinger L
AU  - Benner A
AU  - Döhner K
AU  - Ganser A
PY  - 2026
JO  - Blood
DO  - 10.1182/blood.2025030722
UR  - https://doi.org/10.1182/blood.2025030722
ER  -

APA

H, D., D, S., M, S., W, F., K, G., E, K., J, W., W, V., M, H., M, L., HJ, T., U, G., LL, T., L, F., A, W., D, N., B, H., R, S., U, M., S, V. H., M, R., G, A., S, W., A, C., A, S., VI, G., F, T., P, P., L, B., A, B., K, D., & A, G. (2026). A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.. Blood. https://doi.org/10.1182/blood.2025030722

Source records

pubmed · retrieved 2026-09-25T16:37:09.861Z